Free Trial
NASDAQ:XLO

Xilio Therapeutics Q3 2024 Earnings Report

Xilio Therapeutics logo
$0.70 0.00 (-0.59%)
As of 01:34 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Xilio Therapeutics EPS Results

Actual EPS
-$0.22
Consensus EPS
-$0.25
Beat/Miss
Beat by +$0.03
One Year Ago EPS
N/A

Xilio Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Xilio Therapeutics Announcement Details

Quarter
Q3 2024
Time
Before Market Opens
Conference Call Date
Thursday, November 7, 2024
Conference Call Time
9:00AM ET

Upcoming Earnings

Xilio Therapeutics' Q3 2025 earnings is scheduled for Thursday, November 6, 2025, with a conference call scheduled at 9:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Xilio Therapeutics Earnings Headlines

Leerink Partnrs Brokers Decrease Earnings Estimates for XLO
BREAKING: The House just passed 3 pro-crypto bills!
THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. tc pixel
See More Xilio Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Xilio Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Xilio Therapeutics and other key companies, straight to your email.

About Xilio Therapeutics

Xilio Therapeutics (NASDAQ:XLO), a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

View Xilio Therapeutics Profile

More Earnings Resources from MarketBeat